Xanthosine | 6253-54-9

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: Xanthosine
• 英文别名: 9-(3,4-Dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-3,9-dihydro-purine-2,6-dione；9-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purine-2,6-diol
• CAS: 6253-54-9
• 化学式: C₁₀H₁₂N₄O₆
• 分子量: 284.228
• InChiKey: UBORTCNDUKBEOP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.4
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  146
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cells
  申请人：Gemin X Biotechnologies Inc.

  公开号：US20030119894A1

  公开（公告）日：2003-06-26

  The present invention provides methods for treating or preventing cancer or neoplastic disease comprising administering to a patient a compound having the features of a pharmacophore for human anti-apotptotic Bcl protein inhibitors or identified by the in vitro methods for identifying anti-apotptotic-Bcl protein inhibitors. Also disclosed are methods for inhibiting the growth of a cancer cell or a neoplastic cell, comprising contacting the cancer cell or neoplastic cell with a compound having the features of a pharmacophore for human anti-apoptotic-Bcl protein inhibitors.

  本发明提供了治疗或预防癌症或肿瘤性疾病的方法，包括向患者施用具有人类抗凋亡Bcl蛋白抑制剂药效团特征或通过体外识别抗凋亡Bcl蛋白抑制剂的方法鉴定的化合物。本发明还揭示了抑制癌细胞或肿瘤细胞生长的方法，包括将具有人类抗凋亡Bcl蛋白抑制剂药效团特征的化合物与癌细胞或肿瘤细胞接触。
• COMPOSITIONS AND METHODS FOR DETECTING NEOPLASIA
  申请人：The United States Of America,As Represented By The Secretary, Department Of Health & Human Services

  公开号：EP2948775A2

  公开（公告）日：2015-12-02
• N-ALKYLATION OF ALKALOID COMPOUNDS
  申请人：Willow BioSciences Inc.

  公开号：US20210087593A1

  公开（公告）日：2021-03-25

  Disclosed are methods for converting an alkaloid substrate compound into a N-alkylated alkaloid product compound in the presence of an alkyl donor compound and catalytic quantities of an N-alkyltransferase enzyme capable of converting the alkaloid substrate into an alkylated product. The N-alkyltransferase is obtainable from Ephedra sinica.
• MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20210238595A1

  公开（公告）日：2021-08-05

  One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. The antisense strand of the dsRNA molecule comprises at least one thermally destabilizing nucleotide occurring at a seed region; the dsRNA comprises at least four 2′-fluoro modifications, and the sense strand of the dsRNA molecule comprises ligand, wherein the ligand is an ASGPR ligand. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions.
• Modified RNA Agents with Reduced Off-Target Effect
  申请人：ALNYLAM PHARMACEUTICALS, INC.

  公开号：US20220290145A1

  公开（公告）日：2022-09-15

  One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. The antisense strand of the dsRNA molecule comprises at least one thermally destabilizing nucleotide occurring at a seed region; the dsRNA comprises at least four 2′-fluoro modifications, and the sense strand of the dsRNA molecule comprises ligand, wherein the ligand is an ASGPR ligand. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions.